| A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer | |
| Liu, Xin; Guo, Weijian; Zhang, Wen; Yin, Jiliang; Zhang, Jun; Zhu, Xiaodong; Liu, Tianshu; Chen, Zhiyu; Wang, Biyun; Chang, Jianhua | |
| 刊名 | BMC CANCER
 |
| 2017 | |
| 卷号 | 17 |
| 关键词 | Cetuximab FOLFIRI Gastric cancer Biomarker |
| ISSN号 | 1471-2407 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3614621 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Liu, Xin,Guo, Weijian,Zhang, Wen,et al. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer[J]. BMC CANCER,2017,17. |
| APA | Liu, Xin.,Guo, Weijian.,Zhang, Wen.,Yin, Jiliang.,Zhang, Jun.,...&Li, Jin.(2017).A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.BMC CANCER,17. |
| MLA | Liu, Xin,et al."A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer".BMC CANCER 17(2017). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论